# Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy

> **NCT00424151** · PHASE1,PHASE2 · COMPLETED · sponsor: **Silkiss, Rona Z., M.D., FACS** · enrollment: 12 (actual)

## Conditions studied

- Graves' Dysthyroid Ophthalmopathy
- Thyroid Related Orbitopathy

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00424151
- **Lead sponsor:** Silkiss, Rona Z., M.D., FACS
- **Sponsor class:** INDIV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2010-10-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424151, "Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00424151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*